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Summary
In February 2006, a live, oral, human-bovine reassortant rotavirus vaccine (RotaTeq®) was licensed for use among U.S.
infants. The Advisory Committee on Immunization Practices recommends routine vaccination of U.S. infants with 3 doses of this
rotavirus vaccine administered orally at ages 2, 4, and 6 months. The first dose should be administered between ages 6–12 weeks.
Subsequent doses should be administered at 4–10 week intervals, and all 3 doses should be administered by age 32 weeks.
Rotavirus vaccine can be co-administered with other childhood vaccines. Rotavirus vaccine is contraindicated for infants with a
serious allergic reaction to any vaccine component or to a previous dose of vaccine.
Introduction
Rotavirus is the most common cause of severe gastroenteri-
tis in infants and young children worldwide. In developing
countries, rotavirus gastroenteritis is a major cause of child-
hood death and is responsible for approximately half a mil-
lion deaths per year among children aged <5 years (1).
Rotavirus gastroenteritis results in relatively few childhood
deaths in the United States (approximately 20–60 deaths per
year among children aged <5 years) (2). However, nearly
every child in the United States is infected with rotavirus by
age 5 years, and the majority will have gastroenteritis, result-
ing in approximately 410,000 physician visits, 205,000–
272,000 emergency department (ED) visits, and
55,000–70,000 hospitalizations each year and direct and
indirect costs of approximately $1 billion (3–6) (Figure 1).
This report presents the Advisory Committee on Immuniza-
tion Practices (ACIP) recommendations on use of a live, oral,
human-bovine reassortant rotavirus vaccine (RotaTeq®, pro-
duced by Merck and Company, Whitehouse Station, New
Jersey) that was licensed in February 2006 by the Food and
Drug Administration (FDA) for use among U.S. infants.
FIGURE 1. Estimated number of annual deaths,
hospitalizations, emergency department visits, and episodes









Clinical and Epidemiologic Features
of Rotavirus Disease
Rotavirus infects almost all children by age 5 years, but
severe, dehydrating gastroenteritis occurs primarily among chil-
dren aged 3–35 months. The spectrum of rotavirus illness
ranges from mild, watery diarrhea of limited duration to
severe diarrhea with vomiting and fever that can result in
dehydration with shock, electrolyte imbalance, and death
(7–11). Following an incubation period of 1–3 days, the ill-
ness can begin abruptly, and vomiting often precedes the
onset of diarrhea. Up to one third of patients have a tempera-
ture of >102°F (>39°C). Gastrointestinal symptoms
generally resolve in 3–7 days.
Rotaviruses are shed in high concentrations in the stools of
infected children and are transmitted primarily by the
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fecal-oral route, both through close person-to-person contact
and through fomites (12). Rotaviruses also are probably trans-
mitted by other modes, such as fecally contaminated food and
water and respiratory droplets (13). In the United States,
rotaviruses cause winter seasonal peaks of gastroenteritis, with
activity usually beginning in the southwest United States dur-
ing November–December and spreading to the Northeast by
April–May (5,14,15). In the United States, rotaviruses are
responsible for 5%–10% of all gastroenteritis episodes among
children aged <5 years. However, among the various patho-
gens causing gastroenteritis, rotaviruses lead to the most
severe disease and account for a higher proportion of severe
episodes leading to clinic or hospital visits (8,16). For example,
rotavirus accounts for 30%–50% of all hospitalizations for
gastroenteritis among U.S. children aged <5 years and approxi-
mately 70% of hospitalizations for gastroenteritis during the
seasonal peaks (16–19). Among children aged <5 years in the
United States, 17% of rotavirus hospitalizations occur during
the first 6 months of life, 40% by age 1 year, and 75% by age
2 years (Figure 2) (5). In the first 5 years of life, four of five
children in the United States will have rotavirus gastroenteri-
tis (8,18,20), one in seven will require a clinic or ED visit,
one in 70 will be hospitalized, and one in 200,000 will die
from this disease (4,9).
The risk for rotavirus gastroenteritis and its outcomes does
not appear to vary by geographic region within the United
States. Limited data suggest that children from disadvantaged
socioeconomic backgrounds and premature infants have an
increased risk for hospitalization from gastroenteritis, includ-
ing viral gastroenteritis (21). In addition, children and adults
who are immunocompromised because of congenital immu-
nodeficiency, hematopoetic transplantation, or solid organ
transplantation sometimes experience severe, prolonged, and
even fatal rotavirus gastroenteritis (22–25). Rotavirus also is
an important cause of nosocomial gastroenteritis (7,16,17,26–29).
Among adults in the United States, rotavirus infection causes
gastroenteritis primarily in travelers returning from develop-
ing countries, parents and persons caring for children with
rotavirus gastroenteritis, immunocompromised persons, and
older adults (30).
Laboratory Testing for Rotavirus
Because the clinical features of rotavirus gastroenteritis do
not differ from those of gastroenteritis caused by other patho-
gens, confirmation of rotavirus infection by laboratory test-
ing of fecal specimens is necessary for reliable rotavirus
surveillance and can be useful in clinical settings (e.g., in mak-
ing decisions about use of antimicrobial agents). Rotavirus is
shed in high concentration in the stool of children with gas-
troenteritis (i.e., 1012 viruses/G), so the most widely available
method is antigen detection in the stool by an enzyme immu-
noassay (EIA) directed at an antigen common to all group A
rotaviruses. Several commercial EIA kits are available that are
inexpensive, easy to use, rapid, and highly sensitive (approxi-
mately 90% compared with detection by electron microscopy),
making them suitable for rotavirus surveillance and clinical
diagnosis. Latex agglutination and polyacrylamide gel elec-
trophoresis might be less sensitive than EIA but are used in
some settings. Other techniques, including electron micros-
copy, reverse transcription-polymerase chain reaction, nucleic
acid hybridization, sequence analysis, and culture, are used
primarily in research settings. Rotavirus antigen also has been
identified in the serum of patients 3–7 days after disease onset
(31,32), but routine diagnostic testing is based primarily on
testing of fecal specimens.
Serologic methods that detect a rise in serum antibodies,
primarily enzyme immunoassay for rotavirus serum immu-
noglobulin G (IgG) and immunoglobulin A (IgA) antibod-
ies, have been used to confirm recent infections. In vaccine
trials, the immunogenicity of rotavirus vaccines has been
assessed by measuring rotavirus-specific IgA and neutralizing
antibodies to vaccine strains (33,34).
Morphology, Antigen Composition, and
Immune Response
Rotaviruses are 70-nm nonenveloped RNA viruses in the
family Reoviridae. The viral nucleocapsid is composed of three
concentric shells that enclose 11 segments of double-stranded
RNA. The outermost layer contains two structural viral pro-
teins (VP): VP4, the protease-cleaved protein (P protein) and
VP7, the glycoprotein (G protein). These two proteins define
FIGURE 2. Cumulative age distribution of children
hospitalized with an International Classification of Diseases,
Ninth Revision-Clinical Modifications code for rotavirus
gastroenteritis among children aged <5 years — United
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the serotype of the virus and are considered critical to vaccine
development because they are targets for neutralizing anti-
bodies that might be important for protection (35,36).
Because the two gene segments that encode these proteins can
segregate independently, a typing system consisting of both
P and G types has been developed. Because characterizing the
P types by traditional methods of virus neutralization is diffi-
cult, molecular methods have been used to define genotype
based on sequence analysis. These genotypes correlate well with
known serotypes so the genotypes are tentatively designated
in brackets (e.g., P1A [8]). In the United States, viruses con-
taining six distinct P and G combinations are most prevalent:
P1A[8]G1, P1B[4] G2, P1A[8] G3, P1A[8] G4, P1A[8] G9,
and P2A[6] G9 (37,38) (Figure 3); these strains are generally
designated by their G serotype specificity (serotypes G1-4,
G9). Several animal species (e.g., primates and cows) are sus-
ceptible to rotavirus infection and suffer from rotavirus diar-
rhea, but animal strains of rotavirus differ from those that
infect humans. Although human rotavirus strains that possess
a high degree of genetic homology with animal strains have
been identified (39–41), animal-to-human transmission
appears to be uncommon. However, natural reassortant
animal-human strains have been identified in humans (41),
and two are being investigated as vaccine candidates (42).
Although children can be infected with rotavirus several
times during their lives, initial infection after age 3 months is
most likely to cause severe gastroenteritis and dehydration
(43–45). After a single natural infection, 40% of children are
protected against subsequent infection with rotavirus, 75%
are protected against subsequent rotavirus gastroenteritis, and
88% are protected against severe rotavirus gastroenteritis. Sec-
ond, third, and fourth infections confer progressively greater
protection against severe disease (43).
The immune correlates of protection from rotavirus infec-
tion and disease are not fully understood. Both serum and
mucosal antibodies are probably associated with protection,
and in some studies, serum antibodies against VP7 and VP4
have correlated with protection. However, in other studies,
including vaccine studies, correlation between serum antibody
and protection has been poor (46). The first infection with
rotavirus elicits a predominantly homotypic, serum-
neutralizing antibody response to the virus, and subsequent
infections elicit a broader, heterotypic response (7,47). The
influence of cell-mediated immunity is less clearly understood
but probably is related both to recovery from infection and to
protection against subsequent disease (48,49).
Rationale for Rotavirus Vaccination
Several reasons exist to adopt vaccination of infants as the pri-
mary public health measure for prevention of severe rotavirus
disease in the United States. First, rates of rotavirus illness among
children in industrialized and less-developed countries are simi-
lar, indicating that clean water supplies and good hygiene have
little effect on virus transmission; therefore, further improvements
in water or hygiene are unlikely to have a substantial impact on
disease prevention (8,43,50–52). Second, in the United States, a
high level of rotavirus morbidity continues to occur despite avail-
able therapies. For example, the rate of hospitalizations for gas-
troenteritis in young children declined only 16% during
1979–1995 (5,6), despite the widespread availability of oral
rehydration solutions and recommendations by experts, includ-
ing the American Academy of Pediatrics and CDC, for the use of
oral rehydration solutions in the treatment of dehydrating gas-
troenteritis (53,54). Third, studies of natural rotavirus infection
indicate that initial infection protects against subsequent severe
gastroenteritis, although subsequent asymptomatic infections and
mild disease might still occur (43,55,56). Therefore,
vaccination early in life, which mimics a child’s first natural
infection, will not prevent all subsequent disease, but should pre-
vent most cases of severe rotavirus disease and their sequelae (e.g.,
dehydration, physician visits, hospitalizations, and deaths).
Rotavirus Vaccines
Background
The first rotavirus vaccines were based on monovalent
rotavirus strains isolated from either bovine or rhesus hosts,
but their development was abandoned because of variable
FIGURE 3. Prevalent strains of rotavirus among children aged
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efficacy in clinical trials (57–64). Subsequently, multivalent
animal-human reassortant rotavirus vaccines were developed
by using gene reassortment (65).
In 1998, a rhesus-based tetravalent rotavirus vaccine,
RRV-TV (Rotashield®, Wyeth-Lederle Vaccines and Pediat-
rics) (66), was recommended for routine vaccination of U.S.
infants with 3 doses at ages 2, 4, and 6 months (67). How-
ever, RRV-TV was withdrawn from the U.S. market within
1 year of its introduction because of its association with intus-
susception (68). At the time of its withdrawal, RRV-TV had
not yet been introduced in any other national vaccination pro-
gram globally, and the vaccine was not further tested or used
in any country. The risk for intussusception was most elevated
(>20-fold increase) within 3–14 days after receipt of the first
dose of RRV-TV (69), with a smaller (approximately five-
fold) increase in risk within 3–14 days after the second dose.
Overall, the risk associated with the first dose of RRV-TV was
estimated to be approximately 1 case per 10,000 vaccine
recipients (70). Certain researchers have reassessed the data
on RRV-TV and intussusception and have suggested that the
risk for intussusception was age-dependent and that the abso-
lute number of intussusception events, and possibly the rela-
tive risk for intussusception associated with the first dose of
RRV-TV, increased with increasing age at vaccination (71,72).
However, the World Health Organization Global Advisory
Committee on Vaccine Safety (GACVS), after reviewing all
the available data, concluded that risk for RRV-TV-
associated intussusception was high in infants vaccinated
after age 60 days and that insufficient evidence was available
to conclude that the use of RRV-TV at age <60 days was asso-
ciated with a lower risk (73). GACVS noted that the possibil-
ity of an age-dependent risk for intussusception should be
taken into account in assessing rotavirus vaccines. Postlicensure
surveillance suggested that, besides intussusception, RRV-TV
also was associated with a spectrum of other gastrointestinal
symptoms, including gastroenteritis and bloody stools (74).
A monovalent vaccine based on an attenuated human
rotavirus strain of P1A[8] G1 specificity, RIX 4414 (RotaRix®,
GSK Biologicals, Belgium), has shown a clinical efficacy of
85% against severe rotavirus disease in recent trials (75,76).
In a trial of approximately 60,000 infants, no increase in
intussusception was noted among recipients of the vaccine
versus placebo (77). As of June 2006, RotaRix® is licensed in
approximately 30 countries in Latin America, Africa, Asia,
and in countries of the European Union and has been intro-
duced into national vaccination programs in Brazil, Panama,
and Venezuela. A licensure application has not yet been
submitted in the United States.
Human-Bovine Reassortant
Rotavirus Vaccine (RotaTeq®)
The 2006 U.S. licensed RotaTeq® is a live, oral vaccine
that contains five reassortant rotaviruses developed from
human and bovine parent rotavirus strains (Box) (78). Four
reassortant rotaviruses express one of the outer capsid pro-
teins (G1, G2, G3, or G4) from the human rotavirus parent
strain and the attachment protein (P7[5]) from the bovine
rotavirus parent strain. The fifth reassortant virus expresses
the attachment protein (P1A[8]) from the human rotavirus
parent strain and the outer capsid protein G6 from the
bovine rotavirus parent strain. The parent bovine rotavirus
strain Wistar Calf 3 (WC3) was isolated from a calf with diar-
rhea in Chester County, Pennsylvania, in 1981 and was pas-
saged 12 times in African green monkey kidney cells (79).
The reassortants are propagated in Vero cells using standard
tissue culture techniques in the absence of antifungal agents.
RotaTeq® consists of the five human-bovine reassortants
suspended in a solution of buffer (sodium citrate and phos-
phate) and stabilizer (sucrose) that can be stored refrigerated
at 36°F–46°F (2°C–8°C) for up to 24 months. Each 2-mL
vial of vaccine contains the following minimum concentra-
tion of the reassortants: G1 - 2.2 X 106 infectious units;
G2 - 2.8 X 106 infectious units; G3 - 2.2 X 106 infectious
units; G4 - 2.0 X 106 infectious units; and P1 - 2.3 X 106
infectious units. The vaccine formulation contains sucrose,
sodium citrate, sodium phosphate monobasic monohydrate,
sodium hydroxide, polysorbate 80, and tissue culture media.
Trace amounts of fetal bovine serum might be present. No
preservatives or thimerosal are present.
RotaTeq® has been tested in three phase III trials, includ-
ing a large-scale clinical trial of approximately 70,000 infants in
11 countries, with the United States and Finland accounting
for approximately 80% of all enrolled persons (80). Phase III
trials of RotaTeq® have involved 72,324 infants (36,423 in
the RotaTeq® group, 35,825 in the placebo group, and 76
persons who received a mixed regimen). In these trials, 3 doses
of RotaTeq® were administered orally beginning at age 6–12
weeks with a 4–10-week interval between doses. Data from
these trials on immunogenicity, efficacy, and safety of
RotaTeq® are summarized below.
Immunogenicity
The immune correlates of protection from rotavirus infec-
tion and disease are not fully understood. In clinical trials, a
rise in titer of rotavirus group-specific serum IgA antibodies
was used as one of the measures of the immunogenicity of
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RotaTeq®. Sera were collected before vaccination and
approximately 2 weeks after the third dose, and seroconversion
was defined as a threefold or greater rise in antibody titer from
baseline. Serconversion rates for IgA antibody to rotavirus were
93%–100% among 439 vaccine recipients versus 12%–20%
in 397 recipients of the placebo (80).
When administered simultaneously, a 3-dose series of
RotaTeq® does not diminish the immune response to
Haemophilus influenzae type b conjugate (Hib) vaccine, inac-
tivated poliovirus vaccine (IPV), hepatitis B vaccine, pneu-
mococcal conjugate vaccine, and the diphtheria and tetanus
antigens in diphtheria, tetanus, and pertussis vaccine (DTaP)
(Merck, unpublished data, 2005). Because validation of the
pertussis assays is still under review, insufficient immunoge-
nicity data are available to confirm lack of interference when
RotaTeq® is administered concomitantly with childhood
vaccines to prevent pertussis.
Efficacy
The efficacy of the final formulation of RotaTeq® has been
evaluated in two phase III trials (80,81). In these trials, the
efficacy of RotaTeq® after completion of a 3-dose regimen
against rotavirus gastroenteritis of any severity was 74% (95%
confidence interval [CI] = 67%–79%) and against severe
rotavirus gastroenteritis was 98% (CI = 90%–100%) (Table 1).
Severe rotavirus gastroenteritis was defined as a score >16 on
an established 24-point severity scoring system based on the
intensity and duration of fever, vomiting, diarrhea, and changes
in behavior (80). Efficacy was observed against all G1-4 and
G9 serotypes (Table 2), but relatively few non-G1 rotavirus
cases were reported.
In a large study, the efficacy of RotaTeq® against office vis-
its for rotavirus gastroenteritis was evaluated among 5,673
persons and against ED visits and hospitalizations for rotavirus
gastroenteritis among 68,038 persons during the first 2 years
of life (81). RotaTeq® reduced the incidence of office visits by
86% (CI = 74%–93%), ED visits by 94% (CI = 89%–97%),
and hospitalizations for rotavirus gastroenteritis by 96%
(CI = 91%–98%) (Table 3). Efficacy against all gastroenteri-
tis hospitalizations of any etiology was 59% (CI = 56%–65%).
The efficacy of RotaTeq® in the second rotavirus season post-
vaccination was 63% (CI = 44%–75%) against rotavirus
gastroenteritis of any severity and 88% (CI = 49%–99%)
against severe rotavirus gastroenteritis. Data on the efficacy of
<3 doses of RotaTeq® are limited.
Neither breastfeeding nor concurrent administration of other
childhood vaccines appears to diminish the efficacy of a 3-dose
series of RotaTeq®. Among 1,566 infants breastfed exclusively,
the efficacy of RotaTeq® against rotavirus gastroenteritis of
any severity (68%; CI = 54%–78%) was comparable to that
among 1,632 infants who were never breastfed (68%; CI =
46%–82%). Among 204 vaccinated infants born prematurely
(<37 weeks’ gestation), the point estimate of vaccine efficacy
against rotavirus gastroenteritis of any severity was compa-
rable to that among nonpremature infants (70%; CI = -15%–
95%), but the confidence bounds included zero because of
the small sample size.
BOX. Characteristics of RotaTeq®
Parent animal strain Bovine rotavirus strain
WC3 (P7[5] G6)
Vaccine composition Reassortant strains
G1 x WC3; G2 x WC3;
G3 x WC3; G4 x WC3;
P1A[8] x WC3
Vaccine titer Approximately 2 x 106
infectious units of each
reassortant strain per dose
Cell culture substrate Vero cells
Formulation Liquid requiring no
reconstitution with buffer
and stabilizer




cell culture media, and
trace amounts of fetal
bovine serum. No
thimerosal or preservatives.
Shelf life 24 months at 2°C–8°C
(36°F–46°F)




severity (N=3,484) (N=3,499) % Efficacy (95% CI†)
Any 97 369 73.8 (67.2–79.3)
Severe§ 1 57 98.2 (89.6–100.0)
* Per protocol population (includes only cases that occurred at least 14
days after dose 3).
†Confidence interval.
§Severity score >16 in an established 24-point severity scoring system
based on the intensity and duration of fever, vomiting, diarrhea, and
changes in behavior (81).
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Adverse Events Post-Vaccination
Intussusception
The risk for intussusception was evaluated in 71,725 per-
sons enrolled in phase III efficacy trials. In a large-scale safety
and efficacy trial designed specifically to evaluate the risk for
intussusception (80), parents/legal guardians of all persons were
contacted by telephone or home visit on approximately day
7, 14, and 42 after each vaccination, and every 6 weeks there-
after for up to 1 year after the first dose. Parents were asked
about all serious adverse experiences, including intussuscep-
tion, among enrolled children. Potential intussusception cases
were adjudicated according to a prespecified case definition
that included radiographic, surgical, and autopsy criteria.
For the prespecified 42-day postvaccination endpoint, six
cases of intussusception were observed in the RotaTeq® group
versus five cases of intussusception in the placebo group (mul-
tiplicity adjusted relative risk = 1.6; CI = 0.4–6.4). No evi-
dence of clustering of cases of intussusception was observed
within a 7- or 14-day window post-vaccination for any dose,
the period of greatest risk for intussusception associated with
the RRV-TV vaccine. For the 1-year follow-up period after
administration of the first dose, 13 cases of intussusception
were observed in the RotaTeq® group versus 15 cases of
intussusception in the placebo group (multiplicity adjusted
relative risk: 0.9; CI = 0.4–1.9).
Other Adverse Events
Serious adverse events and deaths were evaluated in 71,725
infants enrolled in phase III trials. Among RotaTeq® and pla-
cebo recipients, the incidence of serious adverse events (2.4%
versus 2.6%, respectively), including deaths (<0.1% [n=25]
versus <0.1% [n=27], respectively), was similar. No deaths
were attributed to vaccination by blinded investigators. The
most common cause of death (accounting for 17 of the 52
deaths) was sudden infant death syndrome (SIDS), and deaths
from SIDS were equally distributed among RotaTeq® and
placebo recipients (n=eight and nine, respectively).
A subset of 11,722 persons was studied in detail to assess
other potential adverse experiences (e.g., fever, diarrhea, and
vomiting). In the 42-day period postvaccination, vaccinees
had a small but statistically significantly greater rate of certain
symptoms compared with placebo recipients, including 1%
excess of vomiting (15% versus 14%, respectively), 3% excess
of diarrhea (24% versus 21%, respectively), 1% excess of
nasopharyngitis (7% versus 6%, respectively), 2% excess of
otitis media (15% versus 13%, respectively), and 0.4% excess
of bronchospasm (1.1% versus 0.7%, respectively). Among
RotaTeq® and placebo recipients, the incidence of reported
episodes of fever (43% versus 43%, respectively) and
hematochezia (0.5% versus 0.3%, respectively) was similar.
In the 7-day postvaccination period, vaccinees had a small
but statistically significantly greater rate of diarrhea, with an
excess of 1% after dose 1 (10% versus 9%, respectively), 3%
after dose 2 (9% versus 6%, respectively), and 3% after any
dose (18% versus 15%, respectively). Similarly, vaccinees had
a small but statistically significantly greater rate of vomiting,
with an excess of 2% after dose 1 (7% versus 5%, respec-
tively) and 2% after any dose (12% and 10%, respectively).
The incidence of fever and irritability during the 7-day
period after any vaccine dose was similar among RotaTeq®
and placebo recipients.
Preterm infants
RotaTeq® or placebo was administered to 2,070 preterm
infants (25–36 weeks’ gestational age; median: 34 weeks) in
the phase III trials. All preterm infants were monitored for
severe adverse events, and a subset of 308 was monitored in
detail for all adverse events. No cases of intussusception were
reported among preterm infants. Among preterm infants
administered RotaTeq® and placebo, the incidence of serious
adverse events (5.5% versus 5.8%, respectively) was similar.
Two deaths each were reported among preterm infants
administered RotaTeq® (one SIDS and one motor-vehicle
accident) and placebo (one SIDS and one unknown cause).
TABLE 2. G serotype-specific efficacy of RotaTeq® against
rotavirus gastroenteritis of any severity
No. of cases*
Vaccine Placebo
Serotype (N=3,484) (N=3,499) % Efficacy (95% CI†)
G1 85 339 75.0 (68.2–80.5)
G2 6 17 63.4 (2.7–88.2)
G3 3 7 55.6 (<0–92.6)
G4 3 6 48.1 (<0–91.6)
G9 1 4 74.1 (<0–99.5)
* Per protocol population (includes only cases that occurred at least 14
days after dose 3).
† Confidence interval.
TABLE 3. Efficacy of RotaTeq® in reducing the rate of health-
care use for rotavirus gastroenteritis
Type of No. of cases* % Rate % Rate
contact Vaccine Placebo  reduction (95% CI†)
Hospitalizations§ 6 144 95.8 (90.5–98.2)
Emergency
department
visits§ 14 225 93.7 (88.8–96.5)
Office visits¶ 13 98 86.0 (73.9–92.5)
* Per protocol population (includes only cases that occurred at least
14 days after dose 3).
† Confidence interval.
§ N = 34,035 vaccine and 34,003 placebo recipients.
¶ N = 2,834 vaccine and 2,839 placebo recipients.
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Shedding and Transmission of Vaccine
Virus
Fecal shedding of vaccine virus was evaluated by EIA in a
subset of persons enrolled in the phase III trials by obtaining
a single stool sample during days 4–6 following each vaccina-
tion visit and from all children who submitted a rotavirus
antigen positive stool specimen at any time. Vaccine virus was
shed in 32 of 360 (8.9%; CI = 6.2%–12.3%) persons after
dose 1, zero of 249 (0; CI = 0%–1.5%) persons after dose 2,
and one of 385 (0.3%; CI = <0.1%–1.4%) after dose 3. In
phase III studies, shedding was observed as early as 1 day and
as late as 15 days after a dose. The potential for horizontal




RotaTeq® is provided in a squeezable plastic dosing tube
with a twist-off cap designed to allow for the vaccine to be
administered directly to infants by mouth. Each tube con-
tains a single 2-mL dose of the vaccine as a liquid buffered-
stabilized solution that is pale yellow in color but might have
a pink tint. This formulation protects the vaccine virus from
gastric acid and stabilizes the vaccine, allowing for storage at
refrigerator temperatures (36°F–46°F [2°C–8°C]) for
24 months. RotaTeq® should be administered as soon as pos-
sible after being removed from refrigeration. Additional
information on stability under conditions other than those
recommended is available by calling 1-800-637-2590.
Cost-Effectiveness Analysis
In an analysis that used estimates of current rotavirus
disease burden, vaccine efficacy, vaccine coverage rates, and
health costs, investigators estimated that a national rotavirus
vaccination program in which 3 doses of RotaTeq® are
administered at ages 2, 4, and 6 months would result in
255,000 fewer physician visits, 137,000 fewer ED visits,
44,000 fewer hospitalizations, and 13 fewer deaths per year
in children aged <5 years. From the health-care perspective
alone, vaccination is likely to be cost-saving at a total cost per
child (including administration costs) of up to $66 per child
(approximately $12 per vaccine dose). A higher-priced vac-
cine would be increasingly unlikely to be cost-saving, and at a
cost of more than $143 per child (approximately $38 per dose),
a rotavirus vaccination program would most likely have a net
cost to the health-care system. From the societal perspective,
vaccination is likely to be cost-saving at a total cost per child
of up to $156 per child (approximately $42 per dose). A
higher-priced vaccine would be increasingly unlikely to be cost-
saving, and at a cost of more than $268 per child (approxi-
mately $79 per dose), a rotavirus vaccination program would
most likely have a net cost to society (CDC, unpublished data,
2006).
Recommendations for the Use
of Rotavirus Vaccine
Routine Administration
ACIP recommends routine vaccination of U.S. infants with
3 doses of rotavirus vaccine administered orally at ages 2, 4,
and 6 months (Table 4). The first dose should be adminis-
tered between ages 6–12 weeks. Subsequent doses should be
administered at 4–10-week intervals, and all 3 doses of vac-
cine should be administered by age 32 weeks. Vaccination
should not be initiated for infants aged >12 weeks because of
insufficient data on safety of the first dose of rotavirus vaccine
in older infants. Vaccine should not be administered after age
32 weeks because of insufficient data on the safety and effi-
cacy of rotavirus vaccine in infants after this age. For infants
in whom the first dose of rotavirus vaccine is inadvertently
administered off label at age >13 weeks, the rest of the rotavirus
vaccination series should be completed as per the schedule
because timing of the first dose should not affect the safety
and efficacy of the second and third dose. Infants who have
had rotavirus gastroenteritis before receiving the full course of
rotavirus vaccinations should still initiate or complete the
3-dose schedule because the initial infection frequently
provides only partial immunity.
Infants who are being breastfed can receive rotavirus vac-
cine. The efficacy of rotavirus vaccine is similar among
breastfed and nonbreastfed infants. Like other vaccines,
rotavirus vaccine can be administered to infants with tran-
sient, mild illnesses, and with or without low-grade fever (82).
Simultaneous Administration
Rotavirus vaccine can be administered together with DTaP,
Hib vaccine, IPV, hepatitis B vaccine, and pneumococcal con-
jugate vaccine. Available evidence suggests that the rotavirus
vaccine does not interfere with the immune response to the
Hib vaccine, IPV, hepatitis B vaccine, and pneumococcal con-
jugate vaccine, and the diphtheria and tetanus antigens in DTaP.
Because validation of the pertussis assays is still under review,
insufficient immunogenicity data are available to confirm lack
of interference of immune responses when rotavirus vaccine
is concomitantly administered with childhood vaccines to
prevent pertussis.
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Contraindications
Rotavirus vaccine should not be administered to infants who
have severe hypersensitivity to any component of the vaccine
or who have experienced a serious allergic reaction to a previ-
ous dose of rotavirus vaccine.
Precautions
Altered Immunocompetence
Practitioners should consider the potential risks and ben-
efits of administering rotavirus vaccine to infants with known
or suspected altered immunocompetence. Children and adults
who are immunocompromised because of congenital
immunodeficiency, hematopoetic transplantation, or solid
organ transplantation sometimes experience severe, prolonged,
and even fatal rotavirus gastroenteritis (22–25). However, no
safety or efficacy data are available for the administration of
rotavirus vaccine to infants who are potentially
immunocompromised, including
• infants with blood dyscrasias, leukemia, lymphomas of
any type, or other malignant neoplasms affecting the
bone marrow or lymphatic system;
• infants on immunosuppressive therapy (including high-
dose systemic corticosteroids);
• infants with primary and acquired immunodeficiency
states, including human immunodeficiency virus/
acquired immunodeficiency syndrome (HIV/AIDS) or
other clinical manifestations of infection with HIV; cellu-
lar immune deficiencies; and hypogammaglobulinemic
and dysgammaglobu-linemic states. Data are insufficient
from the clinical trials to support administration of
rotavirus vaccine to infants with indeterminant HIV
status who are born to mothers with HIV/AIDS; and
• infants who have received a blood transfusion or blood
products, including immunoglobulins, within 42 days.
In general, rotavirus vaccine should be deferred for
42 days following receipt of an antibody-containing
product if possible. However, if the 42-day deferral
would cause the first dose of rotavirus vaccine to be
scheduled for age >13 weeks, a shorter deferral interval
should be used to ensure the first dose is administered
before age 13 weeks.
Acute Gastroenteritis
In usual circumstances, rotavirus vaccine should not be
administered to infants with acute, moderate-to-severe gas-
troenteritis until the condition improves. However, infants
with mild acute gastroenteritis can be vaccinated, particularly
if the delay in vaccination might be substantial and might
make the child ineligible to receive vaccine (e.g., aged
>13 weeks before vaccination is initiated).
Rotavirus vaccine has not been studied among infants with
concurrent acute gastroenteritis. In these infants, the immu-
nogenicity and efficacy of rotavirus vaccine can theoretically
be compromised. For example, infants who receive oral
poliovirus vaccine (OPV) during an episode of acute
TABLE 4. Recommendations and quality of evidence for recommendations for use of rotavirus vaccine
Level of evidence* Strength of evidence†
Recommendations
Routine vaccination at ages 2, 4, and 6 months I A
Administer to breastfed infants I A
Co-administer with DTaP, Hib vaccine, IPV, hepatitis B vaccine, and pneumococcal conjugate vaccine I A
Administer to infants with mild illness I B
Contraindications
Serious allergy to a vaccine component or a previous vaccine dose III B
Precautions
Altered immunocompetence III C
Moderate-to-severe illness, including acute gastroenteritis III C
Chronic gastrointestinal disease III C
History of intussusception III C
Special situations
Premature infants (aged <37 weeks) I B
Infants living in households with immunocompromised persons III C
Infants living in households with pregnant women III C
Regurgitation of vaccine III C
Children hospitalized after vaccination III C
* Level of evidence
I Evidence from randomized controlled trials.
II Evidence from other epidemiologic studies.
III Opinions of authorities.
† Strength of evidence
A Good evidence to support recommendation.
B Fair evidence to support recommendation.
C Insufficient evidence.
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gastroenteritis in some instances have diminished poliovirus
antibody responses to OPV (83).
Moderate-to-Severe Illness
Infants with moderate-to-severe illness should be vaccinated
as soon as they have recovered from the acute phase of the
illness (82). This precaution avoids superimposing adverse
effects of the vaccine on the underlying illness or mistakenly
attributing a manifestation of the underlying illness to the vaccine.
Preexisting Chronic Gastrointestinal Disease
Practitioners should consider the potential risks for and
benefits of administering rotavirus vaccine to infants with
preexisting chronic gastrointestinal disease. Infants with pre-
existing chronic gastrointestinal conditions who are not
undergoing immunosuppressive therapy should benefit from
rotavirus vaccine vaccination, and the benefits outweigh the
theoretical risks. However, the safety and efficacy of rotavirus
vaccine have not been established for infants with these pre-
existing conditions (e.g., congenital malabsorption syndromes,
Hirschsprung’s disease, short-gut syndrome, or persistent
vomiting of unknown cause).
Intussusception
Following administration of a previously licensed rotavirus
vaccine, RRV-TV, an increased risk for intussusception was
observed. Available prelicensure data from a trial of 70,000
infants indicated no evidence of an association between
intussusception and the current vaccine. However, additional
postlicensure surveillance data are required to confirm that
the vaccine is not associated with intussusception at a lower
rate than would have been detected in prelicensure trials. In
addition, data suggest that infants with a history of intussus-
ception might be at higher risk for a repeat episode than other
infants. Therefore, until postlicensure data on safety of
rotavirus vaccine are available, the risks for and the benefits of
vaccination should be considered when vaccinating infants
with a previous episode of intussusception.
Special Situations
Premature Infants (<37 weeks’ gestation)
Practitioners should consider the potential risks for and
benefits of vaccinating premature infants against rotavirus.
Limited data suggest that premature infants are at increased
risk for hospitalization from viral gastroenteritis during their
first year of life (21). In clinical trials, the safety and efficacy
of rotavirus vaccine appears to be similar for premature and
term infants, although a relatively small number of preterm
infants have been evaluated. The lower level of maternal
antibody to rotaviruses in very low birthweight, premature
infants theoretically could increase the risk for adverse reac-
tions from rotavirus vaccine. ACIP supports vaccination of
prematurely born infants if they are at least aged 6 weeks, are
being or have been discharged from the hospital nursery, and
are clinically stable. Until further data are available, ACIP
considers that the benefits of rotavirus vaccine vaccination of
premature infants outweigh the theoretical risks.
Exposure of Immunocompromised Persons to
Vaccinated Infants
Infants living in households with persons who have or are
suspected of having an immunodeficiency disorder or impaired
immune status can be vaccinated. The majority of experts
believe the protection of the immunocompromised household
member afforded by vaccination of young children in the
household outweighs the small risk for transmitting vaccine
virus to the immunocompromised household member and
any subsequent theoretical risk for vaccine virus-associated
disease. To minimize potential virus transmission, all mem-
bers of the household should employ measures such as good
hand washing after contact with the feces of the vaccinated
infant (e.g., after changing a diaper).
Exposure of Pregnant Women to Vaccinated
Infants
Infants living in households with pregnant women can be
vaccinated. The majority of women of childbearing age would
have pre-existing immunity to rotavirus and so the risk for
infection and disease from potential exposure to the attenu-
ated vaccine virus strain is low. In addition, no evidence exist
that rotavirus infection or disease during pregnancy poses any
risk to the fetus. Furthermore, vaccination of young children
would avoid potential exposure of the pregnant women to
wild virus if the unvaccinated infant suffers from rotavirus
gastroenteritis.
Regurgitation of Vaccine
The practitioner should not readminister a dose of rotavirus
vaccine to an infant who regurgitates, spits out, or vomits
during or after administration of vaccine. The infant can
receive the remaining recommended doses of rotavirus vac-
cine at appropriate intervals. Data are limited regarding the
safety of administering a dose of rotavirus vaccine higher than
the recommended dose and on the efficacy of administering a
partial dose. Additional data on safety and efficacy are needed
to evaluate the benefits of and risks for readministration.
Hospitalization After Vaccination
If a recently vaccinated child is hospitalized for any reason, no
precautions other than routine universal precautions need be taken
to prevent the spread of vaccine virus in the hospital setting.
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Reporting of Adverse Events
Any clinically significant or unexpected adverse events that
occur after administration of rotavirus vaccine should be
reported to the Vaccine Adverse Events Reporting System
(VAERS). The National Childhood Vaccine Injury Act
requires health-care providers to report to VAERS any event
listed by the vaccine manufacturer as a contraindication to
subsequent doses of the vaccine or any event listed in the
Reportable Events Table (http://vaers.hhs.gov/reportable.htm)
that occurs within the specified period after vaccination.
Rotavirus vaccine is covered under the general category of
rotavirus vaccines in the Reportable Events Table, and no spe-
cific conditions are listed for reporting. VAERS reporting forms
and information can be requested 24 hours a day at 800-822-
7967 or by accessing VAERS at http://vaers.hhs.gov.
Enhanced Postlicensure Surveillance
for Adverse Events
In prelicensure clinical trials, rotavirus vaccine has not been
associated with any serious adverse events, including intus-
susception. Nevertheless, continued monitoring for adverse
events following introduction of rotavirus vaccine into rou-
tine vaccination programs is important, particularly in light
of the previous experience with RRV-TV. In addition to manu-
facturer-sponsored Phase IV studies, postlicensure monitor-
ing will include enhanced review of adverse events reported to
VAERS. The Vaccine Safety Datalink (VSD) also will be used
to monitor any intussusception risk associated with rotavirus
vaccine and to evaluate any other possible associations that
might be identified through VAERS or in Phase IV studies.
The VSD project includes information on persons enrolled
in eight large health maintenance organizations, with an
annual birth cohort of >90,000 infants. Data on all vaccines
administered within the study population are recorded and
linked with diagnoses from medical encounters to determine
rates of potential adverse events resulting from
vaccination. Recently developed rapid analysis methods allow
VSD to conduct near “real time” monitoring for vaccine
adverse events (84).
Given the background rate of natural intussusception among
U.S. infants (25–38 cases per 100,000 infants) and the large
number of children that are potentially eligible for vaccina-
tion, intussusception cases are expected to occur following
vaccination by chance alone that will be unrelated to the vac-
cine (85). Consequently, intensive postlicensure surveillance
will be necessary to assess the safety of this vaccine against this
rare event.
National Vaccine Injury Compensation
Program
The National Vaccine Injury Compensation Program
(VICP), established by the National Childhood Vaccine
Injury Act, is a no-fault system in which persons thought to
have suffered an injury or death as a result of administration
of a covered vaccine can seek compensation. Persons of all
ages who receive a VICP-covered vaccine are eligible to file a
claim.
The program relies on a vaccine injury table listing the vac-
cines covered by the program and the injuries, disabilities,
illnesses, and conditions (including death) for which com-
pensation can be awarded. Claimants also can prevail for con-
ditions not listed in the table if they can prove causation. To
be eligible for compensation, claims must be filed within
3 years after the first symptom of the vaccine injury, or within
2 years of the vaccine-related death and not more than 4 years
after the start of the first symptom of the vaccine-related
injury from which the death occurred.
Rotavirus vaccine is covered by VICP under the general cat-
egory of rotavirus vaccines in Category XI of the Vaccine
Injury Table (http://www.hrsa.gov/osp/vicp/table.htm). This
category of vaccines does not include any table injuries. Addi-
tional information is available from the following from the
National Vaccine Injury Compensation Program, Health
Resources and Services Administration, Parklawn Building,
Room 11C-26, 5600 Fishers Lane, Rockville, MD 20857 (tele-
phone: 800-338-2382 [24-hour recording] or Internet:
http://www.hrsa.gov/vaccinecompensation).
Future Needs
Surveillance of Rotavirus Gastroenteritis
Rotavirus gastroenteritis is not a reportable disease in the
United States, and testing for rotavirus infection is not always
performed when a child seeks medical care for acute gastroen-
teritis. Establishing rotavirus disease surveillance systems that
are adequately sensitive and specific to document the effec-
tiveness of vaccination programs will be necessary. National
surveillance systems for rotavirus infections include review of
national hospital discharge databases for rotavirus-specific or
rotavirus-compatible diagnoses and reports of rotavirus isola-
tion from a sentinel system of laboratories and surveillance in
three sites that participate in the New Vaccine Surveillance
Network. At state and local levels, additional surveillance
efforts at sentinel hospitals or by review of hospital discharge
databases will be necessary to monitor the impact of the vac-
cine program. Special studies (e.g., case-control studies and
retrospective cohort studies) will be needed to confirm the
effectiveness of rotavirus vaccine in routine programmatic use.
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Detection of Unusual Strains of Rotavirus
A national strain surveillance system of sentinel laborato-
ries has been established at CDC to monitor the prevalence of
rotavirus strains before and after the introduction of rotavirus
vaccines. This system is designed to detect new or unusual
strains that might not be effectively prevented by vaccination
and might affect the success of the vaccination program.
Research
Future research should include studies to determine the
safety and efficacy of rotavirus vaccine administered to
infants born prematurely, infants with immune deficiencies,
infants who live in households with immunocompromised
persons, and infants with chronic gastrointestinal disease.
Postlicensure studies also should be conducted to determine
the relative efficacy of <3 doses of vaccine and to address the
cost effectiveness of vaccination programs in various settings.
Education of Health-Care Providers and
Parents
The success of a rotavirus vaccination program depends on
the acceptance and enthusiasm of physicians and other health-
care providers who care for children and caretakers of infants.
In light of the experience with the withdrawal of RRV-TV
vaccine because of its association with intussusception, some
health-care providers and parents might have concerns about
vaccination with current rotavirus vaccine. Vaccination pro-
gram personnel will benefit from education about rotavirus
disease and rotavirus vaccine. Parental education on rotavirus
gastroenteritis and on the vaccine will be essential to establish
and maintain public confidence in this vaccine and to avoid
confusion caused by cases of gastroenteritis in early childhood
resulting from nonrotaviral etiologies and not preventable by
rotavirus vaccine.
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